Paxlovid is simplest in folks 65 and older, examine finds

TTaking the antiviral therapy Paxlovid can scale back an individual’s likelihood of getting severely unwell with COVID-19. However whereas seniors are inclined to get spectacular safety from the drugs, youthful folks get little profit, new analysis finds.

In a examine revealed Aug. 24 within the New England Journal of Medication, researchers in Israel are offering worthwhile real-world information on how efficient the drugs are in opposition to Omicron. Researchers checked out information from 109,000 sufferers from a serious healthcare group — virtually all of whom had been vaccinated, beforehand contaminated, or each — and tracked their hospitalization and demise charges by age. Nearly 4,000 folks within the examine, which ran from January to March 2022, took Paxlovid.

Individuals 65 years or older had been 73% much less prone to be hospitalized for COVID-19 and about 79% much less prone to die from the illness, in comparison with folks of the identical age who took Paxlovid didn’t take. However folks aged 40 to 64 skilled no statistically vital discount within the threat of hospitalization or demise.

Primarily based on the outcomes, the authors conclude that “no proof of profit in youthful adults was discovered.”

To qualify for Paxlovid, sufferers should be at elevated threat of growing critical sickness from COVID-19. Threat elements embody older age, in addition to medical circumstances resembling weight problems, hypertension, diabetes, and a historical past of coronary heart and kidney failure. However the Israeli information means that age could also be an much more vital consideration when assessing who ought to take it.

Whereas the advantages for seniors are clear, the outcomes name into query whether or not the drug is value taking for folks below the age of 65. It comes with doable unwanted effects, together with diarrhea, muscle ache, a rise in blood strain, and an aftertaste so unhealthy it might probably quickly have an effect on some folks’s capability to eat. Paxlovid additionally interacts with widespread drugs like cholesterol-lowering statins, so some docs advise sufferers to cease or scale back these drugs in the course of the five-day Paxlovid course. And there are growing studies that folks taking Paxlovid are prone to get a rebound an infection, or that the virus will come again after they cease taking the drugs.

A caveat to the examine is that the researchers did not disaggregate information on youthful folks with most cancers and different critical immune-depressing circumstances, who could also be extra prone to profit from Paxlovid than different younger folks — maybe to a larger extent than the information indicated. As extra folks take the medication, docs will higher perceive who advantages most and for whom the advantages outweigh the dangers.

Contact us at letters@time.com.